Copyright
©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1182-1189
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1182
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1182
1 yr survivor patients, n = 101 | 1 yr non-survivor patients, n = 13 | P value | |
Serum OGS (ng/mL)–median (p 25-75) | 2.80 (2.20-4.00) | 4.00 (2.70-10.25) | 0.01 |
Age of liver recipient (yr)-median (p 25-75) | 58 (52-62) | 57 (55-63) | 0.61 |
Serum alpha-fetoprotein (ng/dL)-median (p 25-75) | 7.4 (4.0-21.6) | 8.4 (4.3-130.5) | 0.62 |
Protein (g/dL)-median (p 25-75) | 6.70 (6.10-7.10) | 6.70 (5.58-7.63) | 0.90 |
Leukocytes count–median × 103/mm3 (p 25-75) | 4.57 (3.48-6.01) | 4.52 (3.27-7.77) | 0.89 |
Albumin (g/dL)-median (p 25-75) | 3.29 (2.89-3.99) | 3.47 (3.14-3.93) | 0.45 |
Creatinine (mg/dL)-median (p 25-75) | 0.90 (0.78-1.10) | 1.02 (0.75-1.10) | 0.27 |
BMI (kg/m2)-median (p 25-75) | 27.3 (24.3-29.7) | 28.7 (24.9-31.8) | 0.26 |
Nodules size (cm)-median (p 25-75) | 2.9 (2.0-3.4) | 3.2 (1.8-4.9) | 0.40 |
MELD score-median (p 25-75) | 15 (11-18) | 15 (13-17) | 0.77 |
Age of liver donor (yr)-median (p 25-75) | 51 (35-62) | 62 (49-72) | 0.03 |
Gender female, n (%) | 19 (18.8) | 0 | 0.12 |
Child-Pugh score, n (%) | 0.06 | ||
A | 46 (45.5) | 10 (76.9) | |
B | 29 (28.7) | 3 (23.1) | |
C | 26 (25.7) | 0 | |
Infiltration, n (%) | 32 (31.7) | 3 (23.1) | 0.75 |
Macrovascular invasion, n (%) | 4 (4.0) | 0 | 0.99 |
Microvascular invasion, n (%) | 19 (18.8) | 2 (15.4) | 0.99 |
Multinodular tumor, n (%) | 27 (26.7) | 4 (30.8) | 0.75 |
Portal hypertension, n (%) | 64 (63.4) | 9 (69.2) | 0.77 |
Treatment previously to LT, n (%) | 56 (55.4) | 8 (61.5) | 0.77 |
PEI, n (%) | 26 (25.7) | 5 (38.5) | 0.33 |
RFA, n (%) | 6 (5.9) | 0 | 0.99 |
TACE, n (%) | 18 (17.8) | 3 (23.1) | 0.71 |
Liver resection, n (%) | 3 (3.0) | 0 | 0.99 |
Mixed treatment, n (%) | 3 (3.0) | 0 | 0.99 |
Transplantation technique, n (%) | 0.99 | ||
By-pass | 44 (43.6) | 6 (46.2) | |
Piggy back | 57 (56.4) | 7 (53.8) | |
Degree of tumor differentiation, n (%) | 0.11 | ||
Well | 76 (75.2) | 11 (84.6) | |
Moderate | 24 (23.8) | 1 (7.7) | |
Poor | 1 (1.0) | 1 (7.7) | |
Inside Milan criteria previously to LT, n (%) | 96 (95.0) | 12 (92.3) | 0.53 |
Inside Milan criteria after LT, n (%) | 85 (84.2) | 10 (76.9) | 0.45 |
- Citation: Lorente L, Rodriguez ST, Sanz P, González-Rivero AF, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Cerro P, Portero J, Barrera MA. DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation. World J Hepatol 2022; 14(6): 1182-1189
- URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1182.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1182